東方證券(03958.HK)快報:2021年淨利同比增長97.27%
格隆匯2月9日丨東方證券(03958.HK)發佈2021年業績快報,2021年,中國國內資本市場交投活躍,多項市場指標創歷史新高。公司積極把握市場機遇,各項業務穩中向好,經營業績顯著增長。
2021年全年,公司實現營業收入人民幣243.73億元,實現歸屬於上市公司股東的淨利潤人民幣53.72億元,分別較上年同期增長5.36%和97.27%,主要變動原因為:公司資管、經紀、投行等業務手續費淨收入及聯營企業投資收益同比增長;同時,信用減值計提同比減少。
2021年末,公司總資產人民幣3,265.97億元,歸屬於上市公司股東的所有者權益人民幣641.24億元,分別較上年末增加12.19%和6.51%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.